1. Home
  2. XBP vs MDAI Comparison

XBP vs MDAI Comparison

Compare XBP & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XBP

XBP Europe Holdings Inc.

N/A

Current Price

$2.61

Market Cap

47.0M

ML Signal

N/A

MDAI

Spectral AI Inc.

HOLD

Current Price

$2.00

Market Cap

39.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBP
MDAI
Founded
2020
2013
Country
United States
United States
Employees
10998
78
Industry
Business Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.0M
39.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XBP
MDAI
Price
$2.61
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
10.8K
851.1K
Earning Date
03-19-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$1.13
52 Week High
$8.55
$3.21

Technical Indicators

Market Signals
Indicator
XBP
MDAI
Relative Strength Index (RSI) 27.45 74.30
Support Level $0.59 $2.02
Resistance Level $8.46 $2.82
Average True Range (ATR) 0.48 0.14
MACD -0.05 0.05
Stochastic Oscillator 7.83 100.00

Price Performance

Historical Comparison
XBP
MDAI

About XBP XBP Europe Holdings Inc.

XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. By combining innovation with execution excellence, XBP Global helps businesses reimagine business process automation and enable digital transformation.

About MDAI Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Share on Social Networks: